Home Tags SMARTag technology

Tag: SMARTag technology

Stable, Site-Specific ADC Conjugation with SMARTag® Technology and Innovative Linker

Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.

Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug...

Exelixis and Catalent have signed a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs...

TRPH-222 Shows High Response and a Favorable Safety Profile in Non-Hodgkin’s...

Updated results from its Phase 1 multi-center, open-label, monotherapy study of TRPH-222  (formerly called CAT-02-106) in heavily pre-treated patients with relapsed and/or refractory (R/R)...

Interim Results of Phase I Clinical Trial of TRPH-222 in R/R...

The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...

What to Expect at PEGS Boston 2017: A New Pathway of...

From the Charlestown Navy Yard to the Paul Revere House, the Old State House on Washington Street, the New England Aquarium at Central Wharf...

X